According to the World Health Organization (WHO), Cancer accounts for one in six deaths globally, claiming more lives than AIDS, tuberculosis, and malaria combined. This disease represents a big burden on the healthcare systems worldwide due to high-cost factor for treatment and therapeutics. The patent expiry of several cancer therapeutics has resulted in the entry of Biosimilars which are being incorporated in the treatment of oncology. Due to the high incidence of cancer, the market of Oncology Biosimilars is providing huge growth opportunity to the key vendors. According to the U.S. Food and Drug Administration (FDA), Biosimilars is a biological product that is highly similar to an existing, approved reference product and has no clinically meaningful differences. These are manufactured by different companies on being approved officially for cancer treatment. Oncologic Biosimilars are cost-effective molecules with the same efficacy and potency as original biologics.
The latest study released on the Global Oncology Biosimilars Market by HTF MI Research evaluates market size, trend, and forecast to 2029. The Oncology Biosimilars market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analyzed study to help understand market trends, growth drivers, opportunities and upcoming challenges and about the competitors.
Key Players in This Report Include:
Amgen Inc. (United States), Pfizer Inc. (United States), Celltrion Inc. (South Korea), Biocon Ltd. (India), Roche Holding AG (Switzerland), Sandoz International GmbH (Germany), Samsung Bioepis Co., Ltd. (South Korea), Teva Pharmaceutical Industries Ltd. (Israel), Mylan N.V. (United States), Amneal Pharmaceuticals LLC (United States), Dr. Reddy’s Laboratories Ltd. (India), AstraZeneca PLC (United Kingdom), Merck & Co., Inc. (United States), Fresenius Kabi AG (Germany)
Download Sample Report PDF (Including Full TOC, Table & Figures) @ https://www.htfmarketintelligence.com/sample-report/global-oncology-biosimilars-market
Market Trends:
- The number of FDA approved cancer therapies continues to rise, with 63 cancer drugs launching within the past five years
- Over one-third of trials are using biomarkers to stratify patients, pointing to even more personalized cancer treatments in the futur
Market Drivers:
- Increased prevalence of cancer leading to demand for affordable therapies to treat cancer
- Patent expiry of existing biologics
- Increasing number of alliances for the development of Biosimilars.
Market Opportunities:
- Patent expiry will provide an opportunity to the pharmaceutical companies to manufacture more Biosimilars leading to fuel the market.
Major Highlights of the Oncology Biosimilars Market report released by HTF MI
Market Breakdown by Application (Chemotherapy Support, Targeted Therapy, Monoclonal Antibody Therapies, Others) by Type (Monoclonal Antibody Biosimilars, Hormone Therapy Biosimilars, Chemotherapy Biosimilars, Others) by Indication (Breast Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer, Blood Cancer, Others) by Drug Class (Monoclonal Antibodies, Granulocyte Colony-Stimulating Factor, Others) and by Geography (North America, South America, Europe, Asia Pacific, MEA)
Global Oncology Biosimilars market report highlights information regarding the current and future industry trends, growth patterns, as well as it offers business strategies to helps the stakeholders in making sound decisions that may help to ensure the profit trajectory over the forecast years.
Buy Complete Assessment of Oncology Biosimilars market Now @ https://www.htfmarketintelligence.com/buy-now?format=3&report=5187
Geographically, the detailed analysis of consumption, revenue, market share, and growth rate of the following regions:
- The Middle East and Africa (South Africa, Saudi Arabia, UAE, Israel, Egypt, etc.)
- North America (United States, Mexico & Canada)
- South America (Brazil, Venezuela, Argentina, Ecuador, Peru, Colombia, etc.)
- Europe (Turkey, Spain, Turkey, Netherlands Denmark, Belgium, Switzerland, Germany, Russia UK, Italy, France, etc.)
- Asia-Pacific (Taiwan, Hong Kong, Singapore, Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia).
Objectives of the Report
- -To carefully analyze and forecast the size of the Oncology Biosimilars market by value and volume.
- -To estimate the market shares of major segments of the Oncology Biosimilars
- -To showcase the development of the Oncology Biosimilars market in different parts of the world.
- -To analyze and study micro-markets in terms of their contributions to the Oncology Biosimilars market, their prospects, and individual growth trends.
- -To offer precise and useful details about factors affecting the growth of the Oncology Biosimilars
- -To provide a meticulous assessment of crucial business strategies used by leading companies operating in the Oncology Biosimilars market, which include research and development, collaborations, agreements, partnerships, acquisitions, mergers, new developments, and product launches.
Have a query? Market an enquiry before purchase @ https://www.htfmarketintelligence.com/enquiry-before-buy/global-oncology-biosimilars-market
Points Covered in Table of Content of Global Oncology Biosimilars Market:
Chapter 01 – Oncology Biosimilars Executive Summary
Chapter 02 – Market Overview
Chapter 03 – Key Success Factors
Chapter 04 – Global Oncology Biosimilars Market – Pricing Analysis
Chapter 05 – Global Oncology Biosimilars Market Background
Chapter 06 — Global Oncology Biosimilars Market Segmentation
Chapter 07 – Key and Emerging Countries Analysis in Global Oncology Biosimilars Market
Chapter 08 – Global Oncology Biosimilars Market Structure Analysis
Chapter 09 – Global Oncology Biosimilars Market Competitive Analysis
Chapter 10 – Assumptions and Acronyms
Chapter 11 – Oncology Biosimilars Market Research Methodology
Browse Complete Summary and Table of Content @ https://www.htfmarketintelligence.com/report/global-oncology-biosimilars-market
Key questions answered
- How feasible is Oncology Biosimilars market for long-term investment?
- What are influencing factors driving the demand for Oncology Biosimilars near future?
- What is the impact analysis of various factors in the Global Oncology Biosimilars market growth?
- What are the recent trends in the regional market and how successful they are?
Thanks for reading this article; you can also get individual chapter-wise sections or region-wise report versions like North America, LATAM, Europe, or Southeast Asia.
Contact Us :
Craig Francis (PR & Marketing Manager)
HTF Market Intelligence Consulting Private Limited
Phone: +1 434 322 0091
[email protected]
